This is topic MLHP Running hard today in forum Micro Penny Stocks, Penny Stocks $0.10 & Under at Allstocks.com's Bulletin Board.


To visit this topic, use this URL:
http://www.allstocks.com/stockmessageboard/ubb/ultimatebb.php/ubb/get_topic/f/8/t/025524.html

Posted by jas2mel on :
 
Millenia Hope Biopharma Announces a Major Plant Cell Culture Discovery-the Development of Parthenolide-Free Feverfew
PR Newswire - December 05, 2006 1:34 PM ET


Related Quotes
Symbol Last Chg
MLHP Trade 0.027 +0.0091
Real time quote.

Millenia Hope Biopharma a related company to Millenia Hope Inc. (FRANKFURT: MLF - NASDAQ: OCTBB: MLHP) announced today that it has made a major breakthrough in the cell culture production of Feverfew, a plant whose extracts are used in the cosmetic industry. Feverfew (Tanatecum parthenium) extracts have long been used in natural medicine and the cosmetic industry. However, because of allergic reactions to parthenolide, a major component of the extract, the cosmetic industry has long sought Feverfew extracts that are parthenolide free. Using advanced plant cell culture technologies, Millenia Hope Biopharma has developed a process that produces parthenolide-free extracts. This will make it an ideal ingredient for creams and lotions for the cosmetic industry that focuses on natural plant based ingredients with useful pharmacological properties.

Millenia Hope Biopharma has applied for a patent to protect the industrial process for the production of this novel Feverfew extract. Dr. Bahige M. Baroudy, President and Chief Scientific Officer of Millenia Hope Inc., said, "We are elated that our R&D team was successful in a very short period of time of achieving this milestone of developing an entirely new product. This is a great validation of our Phytomics Technologies. Unlike Feverfew extracts that are obtained directly from plants, our extract is odourless, beige in color and partenolide-free that makes it much more attractive to the cosmetic industry. We have mounted a major endeavour to unravel new properties of our Feverfew extracts. We are confident that this new Feverfew extract will find more applications in the cosmetic industry than already anticipated. Our company and others have been looking for parthenolide-free Feverfew and today's announcement demonstrates our commitment to develop new and practical application of Phytomics, our proprietary plant cell culture platform."

ABOUT MILLENIA HOPE INC & MILLENIA HOPE BIOPHARMA:

Millenia Hope develops innovative treatments and products that enhance the quality of life. We are dedicated to fight major infectious diseases, and promote healthier living. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions. Founded in 1997 the company has initially focussed on the need to bring safe and affordable plant based therapies to market for major third world diseases such as malaria and HIV. The first product in this series is Malarex MMH18. Millenia is also pursuing inhibitors of HIV RNase H (patent application pending). Successful development of a drug that targets HIV RNase H will play an important role in the treatment of HIV/AIDS patients who have become resistant to current therapy. www.milleniahope.com

Millenia Hope Biopharma (MHB) a related company to MHI, founded in 2000, is the world's leading bioresearch firm in Phytomic Technologies, commercializing plant cell-based bioprocesses for the discovery, development and production of natural and novel plant-derived products for the pharmaceutical, cosmetic and nutraceutical industries. Avance Pharma has spent over US$25 million in developing its unique proprietary Phytomics Technologies which now belongs to MHB, including the world's largest collection of highly purified phytochemical fractions to be utilized in the pharmaceutical, cosmetic and nutraceutical industry. MHB also provides a plant based drug discovery platform designed for High Throughput Screening and is currently working with a number of leading multinational corporations such as Pierre Fabre Medicaments. www.mh-b.com
 
Posted by jas2mel on :
 
up 150%
 
Posted by hedfe on :
 
almost at .05 be careful probably will go down as fast it as goes up
 
Posted by hedfe on :
 
4 mms at .05 bid
maybe I should get in [Confused]
 
Posted by paulbest on :
 
quote:
Originally posted by hedfe:
almost at .05 be careful probably will go down as fast it as goes up

yep, straight up/straight down is my prediction also
i lost money in a florida pharm last week, just like this chart
 
Posted by jas2mel on :
 
180% nice
 
Posted by jas2mel on :
 
in and out quickly here
 
Posted by SherriT on :
 
So did anyone get in BEFORE the 180% rise?
 
Posted by hedfe on :
 
200 day is at .06 breaking it down right now!
 
Posted by hedfe on :
 
quote:
Originally posted by SherriT:
So did anyone get in BEFORE the 180% rise?

saw it at .04
never got in
 
Posted by jas2mel on :
 
220%
 
Posted by GameGenie on :
 
This bad boy is gonan run for days... thi sis just the beginig... yesterdays news was excelent as well... new facilities in the heart of Candas biopharm district.

-GameGenie
 
Posted by Sparrow on :
 
So far so good!
 
Posted by jdiddy on :
 
I see .050 coming soon!!
 
Posted by jdiddy on :
 
Yahoo!My Yahoo!Mail Make Y! your home pageYahoo! SearchSearch:Sign In
New User? Sign UpFinance Home -Help


HomeInvestingNews & OpinionRetirementBanking & CreditLoansInsuranceSmall BizSpecial EditionsColumnistsPersonal FinanceInvesting IdeasMarketsCompany FinancesProvidersGet QuotesSymbol LookupFinance Search



Press Release Source: MILLENIA HOPE BIOPHARMA


Millenia Hope Biopharma Announces a Major Plant Cell Culture Discovery-the Development of Parthenolide-Free Feverfew
Tuesday December 5, 1:34 pm ET


MONTREAL, QC and WILMINGTON, DE, Dec. 5 /PRNewswire-FirstCall/ - Millenia Hope Biopharma a related company to Millenia Hope Inc. (FRANKFURT: MLF - NASDAQ: OCTBB: MLHP) announced today that it has made a major breakthrough in the cell culture production of Feverfew, a plant whose extracts are used in the cosmetic industry. Feverfew (Tanatecum parthenium) extracts have long been used in natural medicine and the cosmetic industry. However, because of allergic reactions to parthenolide, a major component of the extract, the cosmetic industry has long sought Feverfew extracts that are parthenolide free. Using advanced plant cell culture technologies, Millenia Hope Biopharma has developed a process that produces parthenolide-free extracts. This will make it an ideal ingredient for creams and lotions for the cosmetic industry that focuses on natural plant based ingredients with useful pharmacological properties.
ADVERTISEMENT


Millenia Hope Biopharma has applied for a patent to protect the industrial process for the production of this novel Feverfew extract. Dr. Bahige M. Baroudy, President and Chief Scientific Officer of Millenia Hope Inc., said, "We are elated that our R&D team was successful in a very short period of time of achieving this milestone of developing an entirely new product. This is a great validation of our Phytomics Technologies. Unlike Feverfew extracts that are obtained directly from plants, our extract is odourless, beige in color and partenolide-free that makes it much more attractive to the cosmetic industry. We have mounted a major endeavour to unravel new properties of our Feverfew extracts. We are confident that this new Feverfew extract will find more applications in the cosmetic industry than already anticipated. Our company and others have been looking for parthenolide-free Feverfew and today's announcement demonstrates our commitment to develop new and practical application of Phytomics, our proprietary plant cell culture platform."

ABOUT MILLENIA HOPE INC & MILLENIA HOPE BIOPHARMA:

Millenia Hope develops innovative treatments and products that enhance the quality of life. We are dedicated to fight major infectious diseases, and promote healthier living. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions. Founded in 1997 the company has initially focussed on the need to bring safe and affordable plant based therapies to market for major third world diseases such as malaria and HIV. The first product in this series is Malarex MMH18. Millenia is also pursuing inhibitors of HIV RNase H (patent application pending). Successful development of a drug that targets HIV RNase H will play an important role in the treatment of HIV/AIDS patients who have become resistant to current therapy. www.milleniahope.com

Millenia Hope Biopharma (MHB) a related company to MHI, founded in 2000, is the world's leading bioresearch firm in Phytomic Technologies, commercializing plant cell-based bioprocesses for the discovery, development and production of natural and novel plant-derived products for the pharmaceutical, cosmetic and nutraceutical industries. Avance Pharma has spent over US$25 million in developing its unique proprietary Phytomics Technologies which now belongs to MHB, including the world's largest collection of highly purified phytochemical fractions to be utilized in the pharmaceutical, cosmetic and nutraceutical industry. MHB also provides a plant based drug discovery platform designed for High Throughput Screening and is currently working with a number of leading multinational corporations such as Pierre Fabre Medicaments. www.mh-b.com

SAFE HARBOR STATEMENTS:

Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts, and expectations of Holley Pharmaceuticals Company Inc. that may be referred to as "forward- looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements and Holley Pharmaceuticals Company Inc. could encounter unanticipated obstacles and delays in developing products, services and markets.
 
Posted by BuckyBarnes on :
 
MONTREAL, QC, and WILMINGTON, DE, Dec. 7 /PRNewswire-FirstCall/ - Millenia Hope Biopharma Inc. (OCT: BB: MLHP - FRANKFURT: MLF) is pleased to announce today that its affiliated company, Millenia Hope Biopharma (MHB), has concluded an agreement to retain Union Securities Ltd, a national securities firm, to act as its sponsor and underwriter for the following: A 10 million convertible debenture, interest rate of 10% per annum, and including assisting MHB with a public listing on the TSX.

ABOUT MILLENIA HOPE INC & MILLENIA HOPE BIOPHARMA:

The company has put in place programs to fight major infectious diseases and promote healthier lives and is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions. Founded in 1997 the company has initially focussed on the need to bring safe and affordable herbal therapies to market for major third world diseases such as malaria and HIV. The first product in this series is MMH(TM)Malarex / MMH(TM)18,. Millenia is also pursuing inhibitors of HIV RNase H (patent application pending). Successful development of a drug that targets HIV RNase H will play an important role in the treatment of HIV/AIDS patients who have become resistant to current therapy. www.milleniahope.com

Millenia Hope Biopharma (MHB) a related company to MHI, founded in 1998, is the world's leading bioresearch firm in Phytomics Technologies, commercializing plant cell-based bioprocesses for the discovery, development and production of natural and novel plant-derived products for the pharmaceutical, cosmetic and nutraceutical industries. MHB has spent over US $25 million in developing its unique proprietary Phytomics Technologies, including the world's largest collection of highly purified phytochemical fractions to be utilized in the pharmaceutical, cosmetic and nutraceutical industry. MHB also provides a plant based drug discovery platform designed for High Throughput Screening and is currently working with a number of leading multinational corporations such as Pierre Fabre Medicaments. www.mh-b.com

SAFE HARBOR STATEMENTS:

Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts, and expectations of Holley Pharmaceuticals Company Inc. that may be referred to as "forward- looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements and Holley Pharmaceuticals Company Inc. could encounter unanticipated obstacles and delays in developing products, services and markets.

SOURCE MILLENIA HOPE BIOPHARMA
 
Posted by mrinos on :
 
crapola! I was watching this one since .06 then it went to .065 and I decided to wait until it dropped a bit NOW .079!!!
 
Posted by mrinos on :
 
bought me some on the dip and glad I did
 
Posted by mrinos on :
 
very nice chart
http://stockcharts.com/h-sc/ui?s=MLHP&p=D&b=5&g=0&id=p84261405907
 
Posted by mrinos on :
 
great chart, watch it!
 
Posted by Hitman on :
 
Gr8
 
Posted by mrinos on :
 
mlhp holding strong! chart is nice looking
 
Posted by mrinos on :
 
.093 HOD and moving
 
Posted by mrinos on :
 
Anyone else following this? .105 HOD!!
 


© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2